Daily Medication Pearl: Ozanimod (Zeposia)
Ozanimod (Zeposia) is indicated for the treatment of multiple sclerosis and moderately to severely active ulcerative colitis in adults.
Medication Pearl of the Day: Ozanimod (Zeposia)
Indication: Ozanimod (Zeposia) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; and moderately to severely active ulcerative colitis (UC) in adults.
- Dosing: The recommended maintenance dosage is 0.92 mg orally once daily.
- Dosage forms: Capsules 0.23 mg, 0.46 mg, 0.92 mg.
- Adverse events: Upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, and hypertension.
- Mechanism of action: Ozanimod is a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5. Ozanimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. Ozanimod has minimal or no activity on S1P2, S1P3, and S1P4. The mechanism by which ozanimod exerts therapeutic effects in MS and UC is unknown but may involve the reduction of lymphocyte migration into the central nervous system and intestine.
Source: pi_zeposia.pdf (bms.com)